A Guide to Pulmonary Arterial Hypertension (PAH) Diagnosis, Treatment, and Referral in Primary Care

A Guide to Pulmonary Arterial Hypertension (PAH) Diagnosis, Treatment, and Referral in Primary Care

On-Demand Webcast

This webcast is based on live proceedings from a symposium conducted at the 2019 Cardiometabolic Risk Summit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Faculty

Michael J. Bloch, MD
Associate Professor, University of Nevada School of Medicine
Medical Director, Renown Institute for Heart and Vascular Health
Reno, NV

Intended Learners

This activity is designed for primary care physicians, family medicine specialists, internists, pediatricians, nurse practitioners, nurses, physician assistants, pharmacists, registered dietitians, certified diabetes educators, and other related healthcare professionals involved in the treatment of patients at risk for cardiometabolic syndrome. 

Learning Objectives

After completing this activity, participants should be able to:

  • Define PAH risk factors and diagnostic criteria for the identification of at-risk and affected patients
  • Evaluate available PAH-specific therapies in terms of their mechanisms of action, efficacy and safety profiles, and potential utility in combination therapy
  • Employ guideline-driven diagnostic, therapeutic, and referral practices for the optimal individualized management of PAH

References used in slides: 

1) Image:Wikipedia.com, accessed Oct 20,2019; 2) European Heart Journal 2016;37;67-119; 3) Eur Respir J 2019;53:1801913; 4) Eur Respir J 2019;53:1801904; 5) Barst RJ, Ann Thoracic Med 20083(1):1-4; 6) Eur Respir J 2019 53:1801889; 7) Eur Heart J 2016;37-119; 8) Eur Heart J 2016;37:903-975; 9) N Eng J Med 2015;373:834-844

Activity Overview

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10 question post-test with a score of 70% or better, and complete the evaluation form.

After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

ACPE Credit Policy

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. The reporting function into CPE Monitor will only be available for 60 days after your completion of the activity.  Under ACPE Policy, NACCME will not be able to report your credit to CPE Monitor after this 60 day period.

Release Date: December 19, 2019
Expiration Date: Decemeber 18, 2020
Estimated time to complete: 30 minutes

Participants who completed the live version of this activity are not eligible to receive credit for this enduring material.

For questions regarding this educational activity, please call 609-371-1137.

For questions on certificate or credit inquiries, please contact the Office of Continuing Education for the University of Arkansas for Medical Sciences (UAMS) at 501-661-7962.

There is no fee associated with this activity.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs (please download here). A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Accreditation

In support of improving patient care, this activity has been planned and implemented by the University of Arkansas for Medical Sciences and North American Center for Continuing Medical Education. University of Arkansas for Medical Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Save

CME

The University of Arkansas for Medical Sciences designates this activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE

The University of Arkansas for Medical Sciences designates this activity for a maximum of 0.50 ANCC contact hours. Nursing contact hours will be awarded for successful completion of program components based upon documented attendance and completion of evaluation materials.

CPE

This knowledge-based activity will provide pharmacists up to 0.50 contact hours or 0.05 CEU. CE credit information, based on verification of live attendance and completion of the program evaluation, will be provided to NABP within 60 days after the activity completion. ACPE #JA0000298-9999-20-106-H01-P


Planning Committee

The planning committee comprises Michael J. Bloch, MD, Susie Seaman, NP; Courtney Bryant, UAMS; Jennifer Browne, Molly, Duda, Mary Johnson, Jennifer Ilcyn, Todd Kunkler, Amanda Steinmayr, and Chris Bolwell, NACCME.

Independent Clinical Reviewer: Peter Oettgen, MD, Associate Professor of Medicine, Harvard Medical School, Director of Preventive Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

Financial Disclosure and Conflicts of Interest

Michael Bloch, MD: Research Support – Recor, AstraZeneca, Vascular Dynamics; Consultant/Honoraria – Recor, Medtronic, Amgen, Esperion, Janssen, Takeda International, Relypsa, Pfizer

Ms. Seaman: Advisory Board—Mölnlycke

Dr. Oetttgen has disclosed no relevant financial relationships with any commercial interests.

Ms. Bryant, Ms. Browne, Ms. Duda, Ms. Johnson, Ms. Ilcyn, Mr. Kunkler, and Ms. Steinmayr, NACCME, have disclosed no relevant financial relationships with any commercial interests.

Chris Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service. All other NACCME planning staff have no financial relationships to disclose.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc.